Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Problem with IP supply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate and compare efficacy and tolerability of the brand-name latanoprost and one of its generic version in subjects with primary open angle glaucoma or ocular hypertension.
This randomized, double-blinded, cross-over design study has a 4 months follow-up. There are two periods of 8 weeks. During the first period, subjects put brand-name latanoprost in one eye and the generic version in the other one. In the second period, drops are switched from one eye to the other. There are intraocular pressure measurements (diurnal curves) on day 0 (before treatment), at 8 weeks (at the end of first period) and at 16 weeks (at the end of second period). Variations of intraocular pressure in each eye will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Generic latanoprost | Experimental | 1 eye drop hs |
|
| Brand-name latanoprost | Active Comparator | 1 eye drop hs |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Generic latanoprost | Drug |
| ||
| Brand-name latanoprost |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Intraocular Pressure (IOP) | Goldman applanation tonometry will be used to measure IOP. | 8 weeks, 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Conjunctival hyperemia | 8 weeks, 16 weeks | |
| Change in corneal staining | Oxford grading scale | 8 weeks, 16 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marie-Josée Fredette, MD, FRCSC | Centre de recherche du CHU de Québec; Université Laval | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre universitaire d'ophtalmologie, Hôpital du Saint-Sacrement, CHU de Québec | Québec | G1S 4L8 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
|
| Change in TSS-IOP (Treatment Satisfaction Survey for IntraOcular Pressure) |
| 8 weeks, 16 weeks |
| ID | Term |
|---|---|
| D005902 | Glaucoma, Open-Angle |
| D009798 | Ocular Hypertension |
| ID | Term |
|---|---|
| D005901 | Glaucoma |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077338 | Latanoprost |
| ID | Term |
|---|---|
| D011461 | Prostaglandins F, Synthetic |
| D011465 | Prostaglandins, Synthetic |
| D011453 | Prostaglandins |
| D015777 | Eicosanoids |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |
Not provided
Not provided